Jason Wu

Jason Wu is an associate in the Business Law department and a member of the Life Sciences group.

Jason focuses his legal practice primarily on mergers and acquisitions as well as venture financings, with an emphasis on representing private equity funds and healthcare companies. He also advises clients across a broad range of industries on business transactions and general corporate matters. He has particular experience assisting startups, and regularly counsels both emerging and established companies on complex capital markets and note offerings, SEC reporting, and ongoing corporate governance and compliance matters.

Jason joined Goodwin full-time in 2023, after being a summer associate in 2022.

Jason’s notable representations include:

• Wix.com in its $1.15 billion convertible notes offering
• Impinj in its $190 million convertible notes offering
• Nova in its $750 million convertible notes offering
• Lyft in its $500 million convertible notes offering
• Cognition Therapeutics in its $30 million direct stock offering
• Ligand in its $460 million convertible notes offering
• Jetty in its merger with Rhino Labs
• Enfusion in its $1.5 billion sale to Clearwater
• Deciphera Pharmaceuticals in its $2.4 billion sale to ONO Pharmaceutical
• Aerovate Therapeutics in its reverse merger with Jade Biosciences and $300 million concurrent financing
• Washington Trust in its upsized stock offering

During law school, Jason was a member of the Southern California Review of Law and Social Justice. He also interned at the Teacher Retirement System of Texas.